<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>510(k)</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>FDA warns makers of HIV tests about test collection kits</title>
      <description>
        <![CDATA[The U.S. FDA’s Center for Biologics Evaluation and Research posted four warning letters to makers of HIV sample collection kits, an example of a shift in FDA enforcement in the IVD space that is still allowed after a historical loss in court.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728252</guid>
      <pubDate>Tue, 27 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728252-fda-warns-makers-of-hiv-tests-about-test-collection-kits</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-headquarters-signage.webp?t=1762209624" type="image/jpeg" medium="image" fileSize="1105340">
        <media:title type="plain">FDA headquarters signage</media:title>
        <media:description type="plain">Credit: Tada Images - stock.adobe.com</media:description>
      </media:content>
    </item>
    <item>
      <title>Naox secures FDA clearance for EEG earbuds</title>
      <description>
        <![CDATA[Naox Technologies SAS secured U.S. FDA 510(k) clearance for Naox Link, its in-ear electroencephalography (EEG) device for clinical use both at home and in health care settings. Naox Link is a pair of earbuds the company hopes will transform how the brain activity is monitored, helping diagnose and track a number of conditions affecting the brain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727574</guid>
      <pubDate>Tue, 06 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727574-naox-secures-fda-clearance-for-eeg-earbuds</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2026/Naox-Link-6jan26.webp?t=1767740518" type="image/jpeg" medium="image" fileSize="69636">
        <media:title type="plain">Naox Link</media:title>
        <media:description type="plain">Naox Link. Credit: Naox Technologies SaS</media:description>
      </media:content>
    </item>
    <item>
      <title>Crescom wins FDA clearance for bone analysis</title>
      <description>
        <![CDATA[Crescom Co. Ltd., an AI musculoskeletal imaging company, gained U.S. FDA 510(k) clearance Dec. 24 for MediAI-BA, its AI-powered pediatric and adolescent bone age analysis software.
Classified as a class II medical device, MediAI-BA evaluates bone age and suggests predicted adult height based on growth plate status assessed by hand and wrist X-ray imaging. Prior clinical trial results demonstrated MediAI-BA had specialist-level accuracy, recording a mean absolute deviation (MAD) of 0.39 years.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727223</guid>
      <pubDate>Wed, 24 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727223-crescom-wins-fda-clearance-for-bone-analysis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Crescom-MediAI-BA-24dec25.webp?t=1766601685" type="image/jpeg" medium="image" fileSize="71686">
        <media:title type="plain">Crescom MediAI-BA</media:title>
        <media:description type="plain">Crescom MediAI-BA bone age analysis software. Credit: Crescom</media:description>
      </media:content>
    </item>
    <item>
      <title>Proverum, Zenflow secure FDA nod for systems to treat BPH</title>
      <description>
        <![CDATA[The U.S. FDA recently cleared two new medical devices to treat benign prostatic hyperplasia, offering men with enlarged prostates additional treatment options which are minimally invasive. The approvals include Proverum Medical Ltd.’s Provee System and Zenflow Inc.’s Zenflow Spring Implant and Delivery System, both are first-line interventional therapeutic options which offer relief to the millions of men living with the condition.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727064</guid>
      <pubDate>Mon, 15 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727064-proverum-zenflow-secure-fda-nod-for-systems-to-treat-bph</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Urology/Benign-prostatic-hyperplasia-BPH-prostate.webp?t=1745267344" type="image/jpeg" medium="image" fileSize="464489">
        <media:title type="plain">Illustration of human anatomy, enlarged prostate</media:title>
      </media:content>
    </item>
    <item>
      <title>Flow Neuro wins FDA nod for at-home device for depression</title>
      <description>
        <![CDATA[Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses mild electrical current to stimulate specific areas of the brain to reduce depressive symptoms in as little as three weeks. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/726753</guid>
      <pubDate>Thu, 11 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726753-flow-neuro-wins-fda-nod-for-at-home-device-for-depression</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Flow-FL-100--on-patient-11dec25.webp?t=1765490232" type="image/jpeg" medium="image" fileSize="381262">
        <media:title type="plain">Flow FL 100 on patient</media:title>
        <media:description type="plain">The Flow FL-100 uses transcranial direct current stimulation (tDCS) to treat depression. Credit: Flow Neuro</media:description>
      </media:content>
    </item>
    <item>
      <title>Heartbeam wins appeal, gains FDA clearance</title>
      <description>
        <![CDATA[Management is beaming with delight at Heartbeam Inc. as the company's appeal strategy paid off with U.S. FDA clearance for its synthetic 12-lead electrocardiogram software for the assessment of arrhythmias. In November, the Santa Clara, Calif.-based company received a Not Substantially Equivalent determination from the agency on its 510(k) application, which could have substantially delayed commercialization. Following a plan disclosed Nov. 28, the company resolved the agency's issues through an appeal process and active engagement and obtained clearance much more quickly than expected.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726743</guid>
      <pubDate>Wed, 10 Dec 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726743-heartbeam-wins-appeal-gains-fda-clearance</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Heartbeam-16dec24.webp?t=1734387689" type="image/jpeg" medium="image" fileSize="333840">
        <media:title type="plain">Heartbeam</media:title>
        <media:description type="plain">Heartbeam Inc.’s on-the-go ECG device. Credit: Heartbeam</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA clears Dexcom Smart Basal for insulin optimization</title>
      <description>
        <![CDATA[Dexcom Inc. received U.S. FDA clearance for its Smart Basal CGM-integrated basal insulin dosing optimizer. Designed for adults with type 2 diabetes using glargine U-100 long-acting insulin therapy, Smart Basal uses data from Dexcom’s G7 15 Day sensor with doses logged by the user to personalize recommendations and adjust long-acting insulin doses, with direction from the patient’s health care provider.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726211</guid>
      <pubDate>Wed, 19 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726211-fda-clears-dexcom-smart-basal-for-insulin-optimization</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/12-8-Dexcom_G7_CGM.webp?t=1719437988" type="image/png" medium="image" fileSize="246353">
        <media:title type="plain">Dexcom G7 CGM</media:title>
        <media:description type="plain">Dexcom Inc.’s G7 continuous glucose monitor.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA clears Withings Beamo, ‘thermometer of the future’</title>
      <description>
        <![CDATA[Withings SA received U.S. FDA clearance for Beamo, its health check-up tool designed to monitor heart and lung function. Described as the ‘thermometer of the future’, Beamo combines the sensors of an electrocardiogram, a stethoscope and a thermometer into a hand-held device to allow users to check their body temperature, cardiac and pulmonary health in less than a minute.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725992</guid>
      <pubDate>Fri, 14 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725992-fda-clears-withings-beamo-thermometer-of-the-future</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Withings-Beamo-14nov25.webp?t=1763156408" type="image/jpeg" medium="image" fileSize="152470">
        <media:title type="plain">Withings Beamo multi-sensor device</media:title>
        <media:description type="plain">Withings Beamo multi-sensor device. Credit: Withings France SA</media:description>
      </media:content>
    </item>
    <item>
      <title>Magstim gets FDA nod for chronic pain treatment</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Magstim Co. Ltd. reported that the U.S. FDA cleared its Magstim Rapid magnetic stimulation system for the treatment of chronic pain. The clearance provides a clinically validated therapy that directly targets neural pathways involved in pain processing to deliver a non-invasive, drug-free treatment for chronic pain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725970</guid>
      <pubDate>Wed, 12 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725970-magstim-gets-fda-nod-for-chronic-pain-treatment</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/magstim-12nov24.webp?t=1762986672" type="image/jpeg" medium="image" fileSize="442082">
        <media:title type="plain">Magstim</media:title>
        <media:description type="plain">Magstim Rapid magnetic stimulation system. Credit: Magstim Co. Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Tulyp emerges from stealth with pressure-driven perfusion system</title>
      <description>
        <![CDATA[Tulyp Medical Inc. has emerged from stealth mode with a pressure-driven perfusion system designed to improve vascular procedures. The company, born out of Sofinnova Partners' medical device accelerator, has submitted the technology to the U.S. FDA for 510(k) clearance following initial clinical results that demonstrated safety and functionality.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725512</guid>
      <pubDate>Tue, 04 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725512-tulyp-emerges-from-stealth-with-pressure-driven-perfusion-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/heart-cardio-data.webp?t=1705604213" type="image/png" medium="image" fileSize="343935">
        <media:title type="plain">Blue heart and data grid</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA approves Medtronic Evolut for expanded redo TAVR indication</title>
      <description>
        <![CDATA[Medtronic plc received U.S. FDA approval for the expanded redo TAVR indication of the Evolut transcatheter aortic valve replacement system. The approval allows for valve-in-valve implantation of a new Evolut valve inside a failed previously implanted TAV made by any manufacturer in patients with severe aortic stenosis considered high-risk for open-heart surgery. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723451</guid>
      <pubDate>Thu, 28 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723451-fda-approves-medtronic-evolut-for-expanded-redo-tavr-indication</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/04-28-Medtronic-Evolut-TAVR.webp?t=1756416491" type="image/png" medium="image" fileSize="545987">
        <media:title type="plain">Evolut device image</media:title>
        <media:description type="plain">Evolut Pro+ TAVR device. Credit: Medtronic plc</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA clears Artrya’s Salix AI coronary plaque module</title>
      <description>
        <![CDATA[The U.S. FDA has cleared Artrya Ltd.’s 510(k) for its Salix coronary plaque (SCP) module that is a bolt-on module to the company’s Salix coronary anatomy platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723205</guid>
      <pubDate>Fri, 22 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723205-fda-clears-artryas-salix-ai-coronary-plaque-module</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Artryas-Salix-22aug25.webp?t=1755894201" type="image/jpeg" medium="image" fileSize="132134">
        <media:title type="plain">Artryas Salix</media:title>
        <media:description type="plain">Artrya Ltd. Salix coronary anatomy software analyzes coronary computed tomography angiogram scans via AI to diagnose coronary artery disease. Credit: Artrya.</media:description>
      </media:content>
    </item>
    <item>
      <title>Neuroone's Onerf wins FDA clearance for trigeminal nerve ablation</title>
      <description>
        <![CDATA[Neuroone Medical Technologies Corp. expanded into treatment of chronic pain with a new U.S. FDA clearance for use of its Onerf system to treat trigeminal nerve pain. The system uses radiofrequency ablation to disrupt pain signals from the nerve to the brain. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723167</guid>
      <pubDate>Mon, 18 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723167-neuroones-onerf-wins-fda-clearance-for-trigeminal-nerve-ablation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Trigeminal_Nerve-18aug25.webp?t=1755553758" type="image/jpeg" medium="image" fileSize="109585">
        <media:title type="plain">Trigeminal Nerve</media:title>
        <media:description type="plain">Diagram of the trigeminal nerve. Credit: BruceBlaus, CC</media:description>
      </media:content>
    </item>
    <item>
      <title>Industry sees need for clarity in FDA draft guidance for 510(k) transfers</title>
      <description>
        <![CDATA[Eleven pages is relatively short for a modern U.S. FDA draft guidance, but two trade associations nonetheless had questions about the FDA draft for transfers of 510(k) devices, such as how the agency defines the holder of the 510(k).]]>
      </description>
      <guid>http://www.bioworld.com/articles/722820</guid>
      <pubDate>Mon, 11 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722820-industry-sees-need-for-clarity-in-fda-draft-guidance-for-510k-transfers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Regulatory-US-FDA-HQ.webp?t=1707859292" type="image/png" medium="image" fileSize="2264756">
        <media:title type="plain">U.S. FDA headquarters</media:title>
      </media:content>
    </item>
    <item>
      <title> Olympus co-launches Swan as new JV for endoluminal GI robotics</title>
      <description>
        <![CDATA[Olympus Corp.’s “active investment” in endoluminal robotics has materialized in a new joint venture med-tech called Swan Endosurgical Inc., with Revival Healthcare Capital LLC.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722652</guid>
      <pubDate>Tue, 05 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722652-olympus-co-launches-swan-as-new-jv-for-endoluminal-gi-robotics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Merger-puzzle-pieces-arrow-hands.webp?t=1644441920" type="image/png" medium="image" fileSize="99873">
        <media:title type="plain">Hands holding arrow-shaped puzzle pieces</media:title>
      </media:content>
    </item>
    <item>
      <title>Caranx Medical gets FDA nod for TAVR software Tavipilot Soft</title>
      <description>
        <![CDATA[Caranx Medical SAS secured clearance from the U.S. FDA for Tavipilot Soft, its AI-powered software which provides real-time intraoperative guidance during transcatheter heart valve replacement (TAVR) procedures. The software, which tracks anatomical and instrumental landmarks in real-time to enable precise and accurate heart valve positioning and delivery, will allow a broader number of cardiologists to perform this complex procedure.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721963</guid>
      <pubDate>Wed, 16 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721963-caranx-medical-gets-fda-nod-for-tavr-software-tavipilot-soft</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Tavipilot-software-7-16.webp?t=1752700234" type="image/png" medium="image" fileSize="329840">
        <media:title type="plain">Tavipilot software</media:title>
        <media:description type="plain">Tavipilot software</media:description>
      </media:content>
    </item>
    <item>
      <title>Synchrony receives FDA OK for Libairty airway clearance system</title>
      <description>
        <![CDATA[Synchrony Medical Ltd. received the greenlight from the U.S. FDA for its Libairty airway clearance system which is expected to transform the lives of people with chronic lung diseases. The company is now looking to raise $5 million in series A funding to support the launch of the product in the U.S. later this year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721953</guid>
      <pubDate>Tue, 15 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721953-synchrony-receives-fda-ok-for-libairty-airway-clearance-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Synchrony-Libairty-system-7-15.webp?t=1752609481" type="image/png" medium="image" fileSize="375287">
        <media:title type="plain">Synchrony’s Libairty airway clearance system</media:title>
        <media:description type="plain">Synchrony’s Libairty airway clearance system</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA greenlights Boston Sci’s Farapulse for persistent AF</title>
      <description>
        <![CDATA[Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in addition to its existing approval for paroxysmal AF. The expanded indication marks the first of several regulatory approvals the company expects in the coming months.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721788</guid>
      <pubDate>Mon, 07 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721788-fda-greenlights-boston-scis-farapulse-for-persistent-af</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/farawave-system-21oct24.webp?t=1729547834" type="image/jpeg" medium="image" fileSize="123935">
        <media:title type="plain">Farawave system</media:title>
        <media:description type="plain">Boston Scientific’s Farapulse system with Farawave Nav ablation catheter Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Rising demand spurs Neurent to open new Neuromark facility</title>
      <description>
        <![CDATA[Amid rising demand for its Neuromark system, Neurent Medical Ltd. opened a new manufacturing facility in Ireland, which will serve as the central hub for the production of the device which treats chronic rhinitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721132</guid>
      <pubDate>Wed, 18 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721132-rising-demand-spurs-neurent-to-open-new-neuromark-facility</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Neuromark-system-18jun25.webp?t=1750281526" type="image/jpeg" medium="image" fileSize="109452">
        <media:title type="plain">Neuromark system</media:title>
        <media:description type="plain">Neuromark system. Credit: Neurent Medical Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA clears Dexcom G7 15 Day</title>
      <description>
        <![CDATA[The battle to claim the continuous glucose monitor with the longest wear time continues with Dexcom Inc.’s G7 15 Day continuous glucose monitor gaining U.S. FDA clearance on April 10 for adults with diabetes. The company said it now takes the lead with the 15-day duration, but Abbott Laboratories also offers 15 days of useful life for its Freestyle Libre 3 plus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718915</guid>
      <pubDate>Fri, 11 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718915-fda-clears-dexcom-g7-15-day</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/12-8-Dexcom_G7_CGM.webp?t=1719437988" type="image/png" medium="image" fileSize="246353">
        <media:title type="plain">Dexcom G7 CGM</media:title>
        <media:description type="plain">Dexcom Inc.’s G7 continuous glucose monitor.</media:description>
      </media:content>
    </item>
    <item>
      <title>Cardiovia Viaone epicardial access system secures US FDA clearance</title>
      <description>
        <![CDATA[Cardiovia Ltd.' Viaone epicardial access system received U.S. FDA clearance for treating cardiac arrhythmias. The device provides clinicians with a safe and minimally invasive technology to reach the heart’s outer surface, known as the pericardial space, without the need for a sharp needle, which can cause perforation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718914</guid>
      <pubDate>Fri, 11 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718914-cardiovia-viaone-epicardial-access-system-secures-us-fda-clearance</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/David-Luria-Ziv-Menshes-11apr25.webp?t=1744404083" type="image/jpeg" medium="image" fileSize="367241">
        <media:title type="plain">David Luria Ziv Menshes</media:title>
        <media:description type="plain">Prof. David Luria (left), Director of Electrophysiology at Hadassah Medical Center, and Ziv Menshes, CEO of Cardiovia. Credit: Cardiovia</media:description>
      </media:content>
    </item>
    <item>
      <title>AI-enhanced mammogram readings are better, but ignored</title>
      <description>
        <![CDATA[AI could significantly improve the value of patient recalls following mammography, but so far radiologists seem reluctant to rely on computer-aided readings. Radiologists tend to trust their own judgment – and that of their colleagues – in mammogram readings far more than AI-based diagnostics, even when the AI is much more accurate, a prospective trial analysis published in Radiology by Karolinska Institutet researchers found.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718902</guid>
      <pubDate>Thu, 10 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718902-ai-enhanced-mammogram-readings-are-better-but-ignored</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Lunit-Insight-MMG-10apr25.webp?t=1744315045" type="image/jpeg" medium="image" fileSize="161168">
        <media:title type="plain">Lunit Insight MMG</media:title>
        <media:description type="plain">Lunit Insight MMG. Credit: Lunit</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA gives nod to Orthocell’s 510(k) for nerve repair product</title>
      <description>
        <![CDATA[The U.S. FDA has cleared regenerative medicine company Orthocell Ltd.’s 510(k) for its nerve repair product, Remplir, paving the way to begin commercial operations in the $1.6 billion U.S. nerve repair market.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718894</guid>
      <pubDate>Wed, 09 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718894-fda-gives-nod-to-orthocells-510k-for-nerve-repair-product</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Orthocell-Remplir-box-9apr25.webp?t=1744229232" type="image/jpeg" medium="image" fileSize="155377">
        <media:title type="plain">Orthocell Remplir</media:title>
        <media:description type="plain">Orthocell Ltd.’s regenerative nerve repair product, Remplir. Credit: Orthocell</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA clears Gleamer, Azmed AI-powered tools for chest X-rays</title>
      <description>
        <![CDATA[Two French startups, Gleamer SAS and Azmed SAS, received clearance from the U.S. FDA  for their AI-powered tools for chest X-rays. They join an increasing number of companies developing software tools to help clinicians detect a range of abnormalities on images, enhancing diagnostic accuracy, reducing delays and improving patient outcomes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/718634</guid>
      <pubDate>Tue, 01 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/718634-fda-clears-gleamer-azmed-ai-powered-tools-for-chest-x-rays</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Lung-cancer-dna.webp?t=1681399693" type="image/png" medium="image" fileSize="1280944">
        <media:title type="plain">Illustration of lung cancer, DNA double helix</media:title>
      </media:content>
    </item>
    <item>
      <title>​US FDA clears Roche’s preeclampsia test</title>
      <description>
        <![CDATA[With rates of preeclampsia skyrocketing, the U.S. FDA’s510(k) clearance of Roche Holding AG’s Elecsys test for preeclampsia offers some hope of reducing the number of women and infants who die or experience life-long consequences from the development of dangerously high blood pressure during late pregnancy and in the days immediately following delivery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716938</guid>
      <pubDate>Fri, 14 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716938-us-fda-clears-roches-preeclampsia-test</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Roche-building.webp?t=1698088417" type="image/jpeg" medium="image" fileSize="310241">
        <media:title type="plain">Roche building</media:title>
        <media:description type="plain">Credit: F. Hoffmann-La Roche Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Essilorluxottica receives US, EU, green light for OTC Audio Glasses</title>
      <description>
        <![CDATA[Essilorluxottica SA received U.S. FDA clearance for its over-the-counter Nuance Audio Glasses, which combines sight and sound technologies, to help people improve their vision and hearing. The device also received a CE mark certification under the Medical Devices Regulation from the EU authorities.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716792</guid>
      <pubDate>Mon, 03 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716792-essilorluxottica-receives-us-eu-green-light-for-otc-audio-glasses</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/ENT/Hearing-loss-illustration.webp?t=1738616487" type="image/jpeg" medium="image" fileSize="191144">
        <media:title type="plain">Hand cupping ear to illustration hearing loss</media:title>
      </media:content>
    </item>
    <item>
      <title>Inflammatix’s Triverity scores FDA clearance for ER sepsis test</title>
      <description>
        <![CDATA[Just a few weeks later than expected, Inflammatix Inc. secured U.S. FDA clearance of the Triverity test system for use in emergency triage of patients with suspected acute infection or sepsis. The molecular blood test is the first to identify bacterial and viral infections and provide an all-cause risk evaluation of the likelihood of developing severe illness.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716154</guid>
      <pubDate>Tue, 21 Jan 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716154-inflammatixs-triverity-scores-fda-clearance-for-er-sepsis-test</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Inflammatix-Triverity-test-system-1-21.webp?t=1737495377" type="image/jpeg" medium="image" fileSize="105056">
        <media:title type="plain">Inflammatix Triverity test system</media:title>
        <media:description type="plain">Inflammatix Inc.’s Triverity test for sepsis runs on the Myrna instrument.</media:description>
      </media:content>
    </item>
    <item>
      <title>Neurophet wins FDA nod for brain AI software, targets US expansion</title>
      <description>
        <![CDATA[On the heels of U.S. FDA approval for Neurophet Aqua, an updated version of its artificial intelligence (AI)-based magnetic resonance imaging analysis software for the brain, Neurophet Inc. is preparing for an IPO in 2025 and expansion into U.S. and European markets.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714490</guid>
      <pubDate>Mon, 25 Nov 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714490-neurophet-wins-fda-nod-for-brain-ai-software-targets-us-expansion</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/NeurophetAqua-25nov24.webp?t=1732571575" type="image/jpeg" medium="image" fileSize="126960">
        <media:title type="plain">Neurophet Aqua</media:title>
        <media:description type="plain">Neurophet Aqua</media:description>
      </media:content>
    </item>
    <item>
      <title>Brightheart secures FDA clearance for software to detect fetal heart defects</title>
      <description>
        <![CDATA[The U.S. FDA granted Brightheart SAS 510(k) clearance for its artificial intelligence software which helps doctors detect congenital heart defects in fetuses. The software will transform prenatal ultrasound evaluations of the fetal heart and improve the outcomes for newborns, Cécile Dupont, Brightheart’s CEO, told BioWorld.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714287</guid>
      <pubDate>Thu, 21 Nov 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714287-brightheart-secures-fda-clearance-for-software-to-detect-fetal-heart-defects</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/BrightHeart-software-21nov24.webp?t=1732227934" type="image/jpeg" medium="image" fileSize="214778">
        <media:title type="plain">BrightHeart software</media:title>
        <media:description type="plain">BrightHeart software in use. Credit: Brightheart</media:description>
      </media:content>
    </item>
    <item>
      <title>Smartcardia’s ECG patch gains FDA nod for outpatient cardiac telemetry</title>
      <description>
        <![CDATA[Smartcardia SA received U.S. FDA clearance for mobile outpatient cardiac telemetry for its seven-lead live ECG monitoring patch and cloud platform. With the approval, the solution can now be used for remote live monitoring of a patient’s ECG and immediately notify clinicians in cases of arrhythmias.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714257</guid>
      <pubDate>Mon, 18 Nov 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714257-smartcardias-ecg-patch-gains-fda-nod-for-outpatient-cardiac-telemetry</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-DNA-and-ECG.webp?t=1667860044" type="image/png" medium="image" fileSize="371012">
        <media:title type="plain">Heart, DNA and ECG</media:title>
      </media:content>
    </item>
  </channel>
</rss>
